Secondary Malignancies Across the Age Spectrum

Seminars in Radiation Oncology

Volumn 20, Issue 1, 2010, Pages 67-78

  Ng, Andrea K ^a   Kenney, Lisa B ^a   Gilbert, Ethel S ^b   Travis, Lois B ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; GYRASE INHIBITOR; MELPHALAN; TAMOXIFEN;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT DISEASE; BREAST CANCER; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CLINICAL FEATURE; DRUG MEGADOSE; HODGKIN DISEASE; HUMAN; LASER COAGULATION; LEUKEMIA; LUNG CANCER; MASTECTOMY; MYELODYSPLASTIC SYNDROME; ONSET AGE; PHYSICAL MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION CARCINOGENESIS; RADIATION DOSE; RETINOBLASTOMA; REVIEW; SARCOMA; SECOND CANCER; SOLID TUMOR; STEM CELL TRANSPLANTATION; TESTIS CANCER; THYROID CANCER;

ADULT; AGE DISTRIBUTION; AGING; BREAST NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GENITAL NEOPLASMS, MALE; HODGKIN DISEASE; HUMANS; INCIDENCE; LIFE STYLE; LUNG NEOPLASMS; MALE; NEOPLASMS, SECOND PRIMARY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETINOBLASTOMA; RISK FACTORS; THYROID NEOPLASMS;

EID: 70549099012     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2009.09.002     Document Type: Review

References (119)

1. Ries L., Melbert D., and Krapcho M. SEER Cancer Statistics Review, 1975-2004 (2007), National Cancer Institute, Bethesda, MD
2. Travis L., Rabkin C., and Brown L. Cancer survivorship-genetic susceptibility and second primary cancers: Research strategies and recommendations. J Natl Cancer Inst 98 (2006) 15-25
3. Neglia J.P., Friedman D.L., and Yasui Y. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst 93 (2001) 618-629
4. Curtis R., Freedman D., and Ron E. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. NIH publication 05-5302 (2006), National Cancer Institute, Bethesda
5. Jenkinson H.C., Hawkins M.M., and Stiller C.A. Long-term population-based risks of second malignant neoplasms after childhood cancer in Britain. Br J Cancer 91 (2004) 1905-1910
6. Meadows A.T., Friedman D.L., and Neglia J.P. Second neoplasms in survivors of childhood cancer: Findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 27 (2009) 2356-2362
7. Mertens A.C., Yasui Y., and Neglia J.P. Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study. J Clin Oncol 19 (2001) 3163-3172
8. Moller T.R., Garwicz S., and Barlow L. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: A population-based study in the Nordic countries. J Clin Oncol 19 (2001) 3173-3181
9. Cardous-Ubbink M.C., Heinen R.C., and Langeveld N.E. Long-term cause-specific mortality among five-year survivors of childhood cancer. Pediatr Blood Cancer 42 (2004) 563-573
10. Neglia J.P., Meadows A.T., and Robison L.L. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 325 (1991) 1330-1336
11. Loning L., Zimmermann M., and Reiter A. Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: Significantly lower risk without cranial radiotherapy. Blood 95 (2000) 2770-2775
12. Bhatia S., Sather H.N., and Pabustan O.B. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 99 (2002) 4257-4264
13. Hijiya N., Hudson M.M., and Lensing S. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 297 (2007) 1207-1215
14. Neglia J.P., Robison L.L., and Stovall M. New primary neoplasms of the central nervous system in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 98 (2006) 1528-1537
15. Walter A.W., Hancock M.L., and Pui C.H. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol 16 (1998) 3761-3767
16. Relling M.V., Rubnitz J.E., and Rivera G.K. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354 (1999) 34-39
17. Hawkins M.M., Wilson L.M., and Stovall M.A. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. BMJ 304 (1992) 951-958
18. Pui C.H., Ribeiro R.C., and Hancock M.L. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325 (1991) 1682-1687
19. Smith S.M., Le Beau M.M., and Huo D. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 102 (2003) 43-52
20. Pui C.H., Relling M.V., and Rivera G.K. Epipodophyllotoxin-related acute myeloid leukemia: A study of 35 cases. Leukemia 9 (1995) 1990-1996
21. van Leeuwen F.E., Chorus A.M., and van den Belt-Dusebout A.W. Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12 (1994) 1063-1073
22. Le Deley M.C., Vassal G., and Taibi A. High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr Blood Cancer 45 (2005) 25-31
23. Haddy N., Le Deley M.C., and Samand A. Role of radiotherapy and chemotherapy in the risk of secondary leukaemia after a solid tumour in childhood. Eur J Cancer 42 (2006) 2757-2764
24. Cavenee W.K., Murphree A.L., and Shull M.M. Prediction of familial predisposition to retinoblastoma. N Engl J Med 314 (1986) 1201-1207
25. Kleinerman R.A., Tucker M.A., and Tarone R.E. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: An extended follow-up. J Clin Oncol 23 (2005) 2272-2279
26. Fletcher O., Easton D., and Anderson K. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 96 (2004) 357-363
27. Marees T., Moll A.C., and Imhof S.M. Risk of second malignancies in survivors of retinoblastoma: More than 40 years of follow-up. J Natl Cancer Inst 100 (2008) 1771-1779
28. Hawkins M.M., Wilson L.M., and Burton H.S. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 88 (1996) 270-278
29. Wong F.L., Boice Jr. J.D., and Abramson D.H. Cancer incidence after retinoblastoma: Radiation dose and sarcoma risk. JAMA 278 (1997) 1262-1267
30. Tucker M.A., D'Angio G.J., and Boice Jr. J.D. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 317 (1987) 588-593
31. Kivela T. Trilateral retinoblastoma: A meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 17 (1999) 1829-1837
32. Kleinerman R.A., Tucker M.A., and Abramson D.H. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 99 (2007) 24-31
33. Constine L.S., Tarbell N., and Hudson M.M. Subsequent malignancies in children treated for Hodgkin's disease: Associations with gender and radiation dose. Int J Radiat Oncol Biol Phys 72 (2008) 24-33
34. Bhatia S., Yasui Y., and Robison L.L. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the Late Effects Study Group. J Clin Oncol 21 (2003) 4386-4394
35. Sankila R., Garwicz S., and Olsen J.H. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: A population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol 14 (1996) 1442-1446
36. Ng A.K., Bernardo M.V., and Weller E. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 100 (2002) 1989-1996
37. Swerdlow A.J., Barber J.A., and Hudson G.V. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment. J Clin Oncol 18 (2000) 498-450
38. Green D.M., Hyland A., Barcos M.P., et al. Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol 18 (2000) 1492-1499
39. Kenney L.B., Yasui Y., and Inskip P.D. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med 141 (2004) 590-597
40. Curtis R.E., Metayer C., and Rizzo J.D. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: An international case-control study. Blood 105 (2005) 3802-3811
41. Mauch P., Ng A., and Aleman B. Report from the Rockefeller Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease. Eur J Haematol Suppl 66 (2005) 68-76
42. Travis L.B., Hill D.A., and Dores G.M. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290 (2003) 465-475
43. van Leeuwen F.E., Klokman W.J., and Stovall M. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95 (2003) 971-980
44. Guibout C., Adjadj E., and Rubino C. Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol 23 (2005) 197-204
45. Travis L.B., Hill D., and Dores G.M. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 97 (2005) 1428-1437
46. Sklar C., Whitton J., and Mertens A. Abnormalities of the thyroid in survivors of Hodgkin's disease: Data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 85 (2000) 3227-3232
47. van Leeuwen F.E., Klokman W.J., and Veer M.B. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 18 (2000) 487-497
48. Sigurdson A.J., Ronckers C.M., and Mertens A.C. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): A nested case-control study. Lancet 365 (2005) 2014-2023
49. Acharya S., Sarafoglou K., and LaQuaglia M. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. Cancer 97 (2003) 2397-2403
50. Black P., Straaten A., and Gutjahr P. Secondary thyroid carcinoma after treatment for childhood cancer. Med Pediatr Oncol 31 (1998) 91-95
51. Tucker M.A., Jones P.H., and Boice Jr. J.D. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res 51 (1991) 2885-2888
52. Schneider A.B., Ron E., and Lubin J. Dose-response relationships for radiation-induced thyroid cancer and thyroid nodules: Evidence for the prolonged effects of radiation on the thyroid. J Clin Endocrinol Metab 77 (1993) 362-369
53. Ronckers C.M., Sigurdson A.J., and Stovall M. Thyroid cancer in childhood cancer survivors: A detailed evaluation of radiation dose response and its modifiers. Radiat Res 166 (2006) 618-628
54. Bassal M., Mertens A.C., and Taylor L. Risk of selected subsequent carcinomas in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Clin Oncol 24 (2006) 476-483
55. Ferme C., Eghbali H., and Meerwaldt J.H. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 357 (2007) 1916-1927
56. Ng A.K., Bernardo M.P., and Weller E. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 20 (2002) 2101-2108
57. Aleman B.M., van den Belt-Dusebout A.W., and Klokman W.J. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21 (2003) 3431-3439
58. Tarbell N.J., Gelber R.D., and Weinstein H.J. Sex differences in risk of second malignant tumours after Hodgkin's disease in childhood. Lancet 341 (1993) 1428-1432
59. Dores G.M., Metayer C., and Curtis R.E. Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J Clin Oncol 20 (2002) 3484-3494
60. Hodgson D.C., Gilbert E.S., and Dores G.M. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 25 (2007) 1489-1497
61. Travis L.B., Gospodarowicz M., and Curtis R.E. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 94 (2002) 182-192
62. Gilbert E.S., Stovall M., and Gospodarowicz M. Lung cancer after treatment for Hodgkin's disease: Focus on radiation effects. Radiat Res 159 (2003) 161-173
63. Swerdlow A.J., Schoemaker M.J., and Allerton R. Lung cancer after Hodgkin's disease: A nested case-control study of the relation to treatment. J Clin Oncol 19 (2001) 1610-1618
64. Travis L.B., Fossa S.D., and Schonfeld S.J. Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 97 (2005) 1354-1365
65. Fossa S.D., Chen J., and Schonfeld S.J. Risk of contralateral testicular cancer: A population-based study of 29,515 U.S. men. J Natl Cancer Inst 97 (2005) 1056-1066
66. Travis L.B., Andersson M., and Gospodarowicz M. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92 (2000) 1165-1171
67. Pedersen-Bjergaard J., Daugaard G., and Hansen S.W. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 338 (1991) 359-363
68. Kollmannsberger C., Hartmann J.T., and Kanz L. Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer 83 (1999) 860-863
69. Vaughn D.J., Gignac G.A., and Meadows A.T. Long-term medical care of testicular cancer survivors. Ann Intern Med 136 (2002) 463-470
70. Hayat M.J., Howlader N., and Reichman M.E. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12 (2007) 20-37
71. Kirova Y.M., Gambotti L., and De Rycke Y. Risk of second malignancies after adjuvant radiotherapy for breast cancer: A large-scale, single-institution review. Int J Radiat Oncol Biol Phys 68 (2007) 359-363
72. Gao X., Fisher S.G., and Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: A population-based study. Int J Radiat Oncol Biol Phys 56 (2003) 1038-1045
73. Boice Jr. J.D., Harvey E.B., and Blettner M. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 326 (1992) 781-785
74. Hill-Kayser C.E., Harris E.E., and Hwang W.T. Twenty-year incidence and patterns of contralateral breast cancer after breast conservation treatment with radiation. Int J Radiat Oncol Biol Phys 66 (2006) 1313-1319
75. Storm H.H., and Jensen O.M. Risk of contralateral breast cancer in Denmark 1943-80. Br J Cancer 54 (1986) 483-492
76. Hooning M.J., Aleman B.M., and Hauptmann M. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol 26 (2008) 5561-5568
77. Clarke M., Collins R., and Darby S. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 366 (2005) 2087-2106
78. Stovall M., Smith S.A., and Langholz B.M. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys 72 (2008) 1021-1030
79. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365 (2005) 1687-1717
80. Fisher B., Costantino J.P., and Redmond C.K. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86 (1994) 527-537
81. Fisher B., Costantino J.P., and Wickerham D.L. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
82. Magriples U., Naftolin F., and Schwartz P.E. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11 (1993) 485-490
83. Bergman L., Beelen M.L., and Gallee M.P. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356 (2000) 881-887
84. Saadat M., Truong P.T., and Kader H.A. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: Comparison of cohorts treated with and without tamoxifen. Cancer 110 (2007) 31-37
85. Brown L.M., Chen B.E., and Pfeiffer R.M. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat 106 (2007) 439-451
86. Roychoudhuri R., Evans H., and Robinson D. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 91 (2004) 868-872
87. Neugut A.I., Robinson E., and Lee W.C. Lung cancer after radiation therapy for breast cancer. Cancer 71 (1993) 3054-3057
88. Zablotska L.B., and Neugut A.I. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer 97 (2003) 1404-1411
89. Deutsch M., Land S.R., and Begovic M. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06. Cancer 98 (2003) 1362-1368
90. Kirova Y.M., De Rycke Y., and Gambotti L. Second malignancies after breast cancer: The impact of different treatment modalities. Br J Cancer 98 (2008) 870-874
91. Travis L.B., Curtis R.E., and Inskip P.D. Re: Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 87 (1995) 60-61
92. Neugut A.I., Murray T., and Santos J. Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer 73 (1994) 1615-1620
93. Ford M.B., Sigurdson A.J., and Petrulis E.S. Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors. Cancer 98 (2003) 1457-1464
94. Kaufman E.L., Jacobson J.S., and Hershman D.L. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 26 (2008) 392-398
95. Zablotska L.B., Chak A., and Das A. Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer. Am J Epidemiol 161 (2005) 330-337
96. Huang J., and Mackillop W.J. Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer 92 (2001) 172-180
97. Karlsson P., Holmberg E., and Samuelsson A. Soft tissue sarcoma after treatment for breast cancer-a Swedish population-based study. Eur J Cancer 34 (1998) 2068-2075
98. Kirova Y.M., Vilcoq J.R., and Asselain B. Radiation-induced sarcomas after radiotherapy for breast carcinoma: A large-scale single-institution review. Cancer 104 (2005) 856-863
99. Rubino C., de Vathaire F., and Shamsaldin A. Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer 89 (2003) 840-846
100. Jessner M., Zak F.G., and Rein C.R. Angiosarcoma in postmastectomy lymphedema (Stewart-Treves syndrome). AMA Arch Derm Syphilol 65 (1952) 123-129
101. Esler-Brauer L., Jaggernauth W., and Zeitouni N.C. Angiosarcoma developing after conservative treatment for breast carcinoma: Case report with review of the current literature. Dermatol Surg 33 (2007) 749-755
102. Virtanen A., Pukkala E., and Auvinen A. Angiosarcoma after radiotherapy: A cohort study of 332,163 Finnish cancer patients. Br J Cancer 97 (2007) 115-117
103. Simonart T., and Heenen M. Radiation-induced angiosarcomas. Dermatology 209 (2004) 175-176
104. Curtis R.E., Boice Jr. J.D., and Stovall M. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326 (1992) 1745-1751
105. Praga C., Bergh J., and Bliss J. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23 (2005) 4179-4191
106. Campone M., Roche H., and Kerbrat P. Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. Ann Oncol 16 (2005) 1343-1351
107. Smith R.E., Bryant J., and DeCillis A. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 21 (2003) 1195-1204
108. Chen P.Y., and Vicini F.A. Partial breast irradiation: patient selection, guidelines for treatment, and current results. Front Radiat Ther Oncol 40 (2007) 253-271
109. Moon K., Stukenborg G.J., and Keim J. Cancer incidence after localized therapy for prostate cancer. Cancer 107 (2006) 991-998
110. Kendal W.S., Eapen L., and Macrae R. Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer. Int J Radiat Oncol Biol Phys 65 (2006) 661-668
111. Chrouser K., Leibovich B., and Bergstralh E. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol 174 (2005) 107-110 discussion 110-101
112. Pickles T., and Phillips N. The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984-2000. Radiother Oncol 65 (2002) 145-151
113. Brenner D.J., Curtis R.E., and Hall E.J. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88 (2000) 398-406
114. Guckenberger M., and Flentje M. Intensity-modulated radiotherapy (IMRT) of localized prostate cancer: A review and future perspectives. Strahlenther Onkol 183 (2007) 57-62
115. Kry S.F., Salehpour M., and Followill D.S. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 1195-1203
116. Pulte D., Gondos A., and Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood 113 (2009) 1408-1411
117. Preston D.L., Mattsson A., and Holmberg E. Radiation effects on breast cancer risk: A pooled analysis of eight cohorts. Radiat Res 158 (2002) 220-235
118. Inskip P., Robison L., and Stovall M. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 27 (2009) 3901-3907
119. Emmons K.M., Puleo E., and Mertens A. Long-term smoking cessation outcomes among childhood cancer survivors in the Partnership for Health Study. J Clin Oncol 27 (2009) 52-60